Search Results - Turpuseema, T

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    First‐in‐Human (FIH) Study of the Fully‐Human Kappa‐Lambda CD19/CD47 Bispecific Antibody TG‐1801 in Patients with B‐Cell Lymphoma

    First‐in‐Human (FIH) Study of the Fully‐Human Kappa‐Lambda CD19/CD47 Bispecific Antibody TG‐1801 in Patients with B‐Cell Lymphoma by Hawkes, E. A., Lewis, K. L., Doo, N. Wong, Patil, S. S., Miskin, H. P., Sportelli, P., Kolibaba, K. S., Normant, E., Turpuseema, T., Cheah, C. Y.

    Published in Hematological oncology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Hawkes, E A, Lewis, K L, Doo, N Wong, Patil, S S, Miskin, H P, Sportelli, P, Kolibaba, K S, Normant, E, Turpuseema, T, Cheah, C Y

    Published in Hematological oncology
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

    First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma by Hawkes, Eliza, Lewis, Katharine L., Wong Doo, Nicole, Patil, Sushrut S., Miskin, Hari P., Sportelli, Peter, Kolibaba, Kathryn S., Normant, Emmanuel, Turpuseema, Tejasvi, Cheah, Chan Y.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach

    Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach by Roeker, Lindsey E., Feldman, Tatyana A., Soumerai, Jacob D., Falco, Victoria, Panton, Gail, Dorsey, Colleen, Zelenetz, Andrew D., Falchi, Lorenzo, Park, Jae H., Straus, David J., Velasquez, Camila Pena, Lebowitz, Sonia, Fox, Yehudit, Battiato, Kristen, Laudati, Carissa, Thompson, Meghan C., McCarthy, Elizabeth, Kdiry, Sabrina, Martignetti, Rosalba, Turpuseema, Teja, Purdom, Michelle, Paskalis, Dana, Miskin, Hari P., Sportelli, Peter, Leslie, Lori A., Mato, Anthony R.

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

    Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach by Roeker, Lindsey E, Feldman, Tatyana A, Soumerai, Jacob D, Falco, Victoria, Panton, Gail, Dorsey, Colleen, Zelenetz, Andrew D, Falchi, Lorenzo, Park, Jae H, Straus, David J, Pena Velasquez, Camila, Lebowitz, Sonia, Fox, Yehudit, Battiato, Kristen, Laudati, Carissa, Thompson, Meghan C, McCarthy, Elizabeth, Kdiry, Sabrina, Martignetti, Rosalba, Turpuseema, Teja, Purdom, Michelle, Paskalis, Dana, Miskin, Hari P, Sportelli, Peter, Leslie, Lori A, Mato, Anthony R

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

    Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies by Cheah, Chan Y., Wickham, Nicholas, Yannakou, Costas K., Lewis, Katharine L, Hui, Chi-Hung, Tang, Pek Sang, Turpuseema, Tejasvi, Miskin, Hari P, Tang, Jian-Ping, Normant, Emmanuel, Ricart, Alejandro D., Tam, Constantine S.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Abstract 5790: TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in pre-clinical models

    Abstract 5790: TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in pre-clinical models by Normant, Emmanuel, Gorelik, Leonid, Shmeis, Rama, Le, Henry, Nisch, Robert, TenHuisen, Karen, Turpuseema, Teja, Oliviero, James, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S.

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: